ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
Mercedes
Garayoa Berrueta
Investigadora desde null
Publicaciones en las que colabora con Mercedes Garayoa Berrueta (27)
2021
-
Bone marrow mesenchymal stromal cells in multiple myeloma: Their role as active contributors to myeloma progression
Cancers, Vol. 13, Núm. 11
-
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
Cells, Vol. 10, Núm. 3
2020
-
Filanesib for the treatment of multiple myeloma
Expert Opinion on Investigational Drugs, Vol. 29, Núm. 1, pp. 5-14
-
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Haematologica
-
Protein translation inhibition is involved in the activity of the pan-pim kinase inhibitor pim447 in combination with pomalidomide-dexamethasone in multiple myeloma
Cancers, Vol. 12, Núm. 10, pp. 1-20
2019
-
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Cells, Vol. 8, Núm. 11
2017
-
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Journal of Hematology and Oncology, Vol. 10, Núm. 1
-
Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone
Haematologica, Vol. 102, Núm. 1, pp. 168-175
-
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
Haematologica, Vol. 102, Núm. 12, pp. 2113-2124
-
The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care
Clinical Cancer Research, Vol. 23, Núm. 1, pp. 225-238
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
-
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines
PLoS ONE, Vol. 9, Núm. 3
-
Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease
Clinical Cancer Research, Vol. 20, Núm. 6, pp. 1542-1554
-
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease
Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305
2013
-
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Blood, Vol. 122, Núm. 22, pp. 3591-3598
-
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications
Investigational New Drugs, Vol. 31, Núm. 1, pp. 200-205
-
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
Leukemia, Vol. 27, Núm. 2, pp. 430-440
2012
-
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
Haematologica, Vol. 97, Núm. 7, pp. 1110-1114
-
Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects
PLoS ONE, Vol. 7, Núm. 4
-
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma
Annals of Hematology, Vol. 91, Núm. 2, pp. 257-269